Dafne Salas-Cuadros, MD

From 🇵🇪 in 🇺🇸 | Aspiring Internist | MD @UNSA_Oficial | MMSc in Immunology graduate @CayetanoHeredia | Certified @ECFMG_IMG

[TidalHealth @MyTidalHealth]

Today we officially welcome our new residents and fellows to TidalHealth! We're excited to have you on site and look forward to supporting you throughout your training journey. Wishing each of you a successful, rewarding year ahead!

[Dafne Salas-Cuadros, MD @_DafneSC]

#Match2025 #MatchDay2025

https://t.co/Cfz6Csvpes

[Dafne Salas-Cuadros, MD @_DafneSC]

Thanks to my dearest friends; this is for you as well.
@eyadomaya, @tonyfeliciano25, @lorena20515, @HersonFS, @OSerrano17, @NavairaShoaib99, @Kasandr40 🙏

[Dafne Salas-Cuadros, MD @_DafneSC]

I am beyond thrilled to share that 🌟 I MATCHED 🌟 in IM at @MyTidalHealth 🎉

A huge thank you to @UNSA_Oficial, @AAPPHealth, Dr Jorge Ballon, Dr Jinsong Zhang, Dr @pongasg, Dr Stephanie Clauss, my amazing husband @MaqueYvan💙and everyone who supported this journey #Match2025

[Eric Topol @EricTopol]

After we reach advanced age, around 80, the propensity to develop cancer is markedly reduced. A discovery reported @Nature today about aged stem cells and iron insufficiency may help explain this advantage
https://t.co/Cnqb924Fxl @NatureNV
https://t.co/HYqc20ZTe7

[Yakup Ergün @dr_yakupergun]

Epigenetics-targeted drugs: current paradigms and future challenges

Many drugs are being developed in every field of oncology👇

https://t.co/ykWjARprot

[Paolo Tarantino @PTarantinoMD]

Happy Thanksgiving with the most impressive KM curve you’ll see today.

PFS for first line nivo/ipi vs chemo in MSI-H mCRC.

🛻 Truck test: <0.001

https://t.co/mVwx1M8K3i

[Yakup Ergün @dr_yakupergun]

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

2y PFS➡️72% vs 14%

💥When the right drug is given to the right patient at the right time, the survival curves can be as perfect as the one below👇

https://t.co/UWHFjuLOzq

[Steve Rattner @SteveRattner]

Over the last 50 years, 101 million infants around the world were saved by vaccines. Elevating anti-vaccine conspiracy theories would cost lives. @Morning_Joe

[Dafne Salas-Cuadros, MD @_DafneSC]

Hey @AAPPHealth, let’s keep an eye on things and see if this shifts the direction for the new exam takers.

[USMLE @TheUSMLE]

The USMLE Management Committee will review the passing standard for Step 1 at its Dec. 2024 meeting. If it's determined that a change is appropriate, the new passing standard will become effective for all examinees who take Step 1 on or after Jan. 1, 2025. https://t.co/jf8HJtKYGB

[Dafne Salas-Cuadros, MD @_DafneSC]

@AutoimmuneGAI

[Dafne Salas-Cuadros, MD @_DafneSC]

Talking about inflammation …

[Dafne Salas-Cuadros, MD @_DafneSC]

@dr_yakupergun @Cancer_Cell @tonyfeliciano25 lo que estabas buscando :D

[The American Association of Immunologists (AAI) @ImmunologyAAI]

To understand #autoimmunity, you have to first understand #immunity. @JamesLillard1 walks through the different types of immunity and their role in the immune response. Check out #ImmunologyExplained to learn more: https://t.co/MgvUGi6GJd.

[Dafne Salas-Cuadros, MD @_DafneSC]

@DrAlexSanc79477 @AAPPHealth So right

[Dafne Salas-Cuadros, MD @_DafneSC]

#NewProfilePic

[SAOM @saom_oncologia]

📣 NUEVA FORMACIÓN: El próximo lunes 11 noviembre celebramos el Webinar #CáncerdePulmón MAP (Programa de Ayuda MDT) - Fase II, que cuenta con la colaboración de @AstraZenecaES.

💻 Sesión virtual
👉 Acceso a inscripción y programa: https://t.co/wd64oO9Yh0

🚀 ¡No te la pierdas!

[Dr. Antonio Calles 🫁🚭 @Tony_Calles]

💥 The end of Pembro reign?
Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: HARMONi-2 #WCLC24 #LCSM

[Therapeutic Advances in Medical Oncology @TAMedOncol]

BLU-945, a next-gen EGFR TKI, shows promise against osimertinib-resistant NSCLC, shrinking tumors in preclinical models and in patients from the SYMPHONY trial. This could help fill treatment gaps for EGFR-mutant lung cancer.

Read more:
https://t.co/j2ulY3r6Fc